Breye raises €67.5M for diabetic eye disease trial with Novo Holdings backing
Danish biotech Breye Therapeutics has raised €67.5 million to advance an oral eye disease drug candidate into a Phase 2 clinical trial.
ADVERTISEMENT
About Nick Paul Taylor
This author has not written his bio yet.
But we are proud to say that Nick Paul Taylor contributed 23 entries already.
Entries by Nick Paul Taylor
MaaT’s bid to overturn microbiome approval refusal suffers setback
MaaT Pharma has received a “negative trend” opinion in response to its request for EMA to re-examine its opposition to approving a microbiome therapy.
Genfit plans Phase 2 liver failure trial after acquiring immunomodulator from Inotrem
French biotech Genfit acquired nangibotide from Inotrem in the summer and plans to start a Phase 2a trial in acute-on-chronic liver failure (ACLF) in the fourth quarter.
Amyl Tx raises €8.25M to develop universal neurodegeneration drug
Belgian biotech Amyl Therapeutics has completed an €8.25 million Series A extension to fund work on its universal treatment for neurodegenerative diseases.
Redx raises $36M to fund Phase 2 Crohn’s disease trial
UK-based Redx Pharma has closed a $36 million (€31 million) Series A financing round to support a Phase 2 trial of its Crohn’s disease drug candidate.
ASCO: Immatics posts data on PRAME pipeline ahead of pivotal readout
Immatics has published a series of updates on its PRAME pipeline, using the American Society for Clinical Oncology (ASCO) Annual Meeting to share data on its lead candidate and next-generation program.
GSK reports 19% functional cure rate for near-approval hepatitis B drug
GSK has linked its chronic hepatitis B drug candidate to a 19% functional cure rate across a pair of Phase III trials, clearing the bar it set for clinical relevance.
Ex-Palantir execs raise $12M to develop AI operating system at Perceptic
Perceptic has raised a $12 million (€10.3 million) seed round to advance an AI operating system used by companies including CSL.
Adcendo inks MSD supply deal to run ADC-Keytruda combination study
Adcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor.
Days after J&J update, Nanobiotix pauses trading amid €75M stock offering
Nanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect.